• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Upexi Inc.

    9/24/25 5:18:57 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $UPXI alert in real time by email
    S-8 1 upxi_s8.htm FORM S-8 upxi_s8.htm

    As filed with the Securities and Exchange Commission on September 24, 2025    

     

    Registration No. 333-[__________]

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    UPEXI, INC.

    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware

     

    83-3378978

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

     

     

     

    3030 North Rocky Point Drive, Suite 420

    Tampa, FL

     

    33607 

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Upexi, Inc. 2019 Incentive Stock Plan

    (as Amended and Restated as of August 19, 2025)

    (Full Title of the Plan)

     

    Andrew J. Norstrud

    3030 North Rocky Point Drive, Suite 420

    Tampa, FL 33607

    (701) 353-5425

    (Name, Address, and Telephone Number, Including Area Code, of Agent for Service)

     

    Copies to:

    Clint C. Gage

    Rasika A. Kulkarni

    Dickinson Wright PLLC

    350 East Las Olas Blvd, Suite 1750

    Ft. Lauderdale FL 33301

    (954) 991-5420

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company" in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

        

    EXPLANATORY NOTE

    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

     

    Pursuant to General Instruction E of Form S-8, Upexi Inc., a Delaware corporation (the “Company” or the “Registrant”, f/k/a Grove, Inc.), is filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the “Commission”) to register 24,500,000 additional shares of common stock, par value $0.00001 per share, of the Company (the “Common Stock”) for issuance pursuant to the Upexi, Inc. 2019 Incentive Stock Plan (as amended from time to time, the “2019 Plan”). The Company originally authorized 277,778 shares of Common Stock for issuance as incentive awards under the 2019 Plan. The Board further amended the 2019 Plan by increasing the authorized shares thereunder by 222,222 shares of Common Stock to an aggregate of 500,000 shares, which amendment was approved by the shareholders at a meeting held on May 24, 2022. On April 19, 2025, the Board approved to increase the authorized shares under the 2019 Plan by an additional 9,500,000 to an aggregate of 10,000,000 shares of Common Stock. The shareholders approved this amendment at the annual meeting of the shareholders held on June 16, 2025. Thereafter, on June 19, 2025, the Board approved to increase the authorized shares under the 2019 Plan by an additional 15,000,000 to an aggregate of 25,000,000 shares of Common Stock. The shareholders approved this amendment at the special meeting of the shareholders held on August 19, 2025.

     

    This Registration Statement registers an aggregate of 24,500,000 additional shares of Common Stock, comprised of (i) 2,750,000 shares of Common Stock issued or issuable pursuant to exercise of options and/or vesting of restricted stock awards made under the Incentive Plan, and (ii)  21,750,000 shares of Common Stock that are reserved for issuance pursuant to future awards under the Incentive Plan.

     

    In connection with the 2019 Plan, the Registrant previously filed with the Commission registration statements on Form S-8 (Registration Nos. 333-257491 and 333-273859) on June 29, 2021 and August 9, 2023, respectively (the “Prior Registration Statements”) collectively registering 500,000 shares of Common Stock. In accordance with General Instruction E to Form S-8, the Registrant hereby incorporates by reference the contents of the Prior Registration Statements, except to the extent supplemented, superseded or modified by the specific information set forth below or the specific exhibits attached hereto.

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    All information required by Part I to be contained in the prospectus is omitted from this Registration Statement in accordance with the explanatory note to Part I of Form S-8 and Rule 428 under the Securities Act of 1933, as amended (the "Securities Act"). Documents containing the information required by Part I of the Registration Statement will be sent or given to Plan participants as specified by Rule 428(b)(1) under the Securities Act.

     

     
    2

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the Commission:

     

     

    (a)

    Annual Report on Form 10-K for the fiscal year ended June 30, 2025 filed with the Commission on September 24, 2025; and

     

     

     

     

    (b)

    The description of our Capital Stock contained in Exhibit 4.1 of our Registration Statement on this Form S-8 filed with the Commission on September 24, 2025.

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the respective dates of filing of such documents (such documents, and the documents enumerated above, being hereinafter referred to as "Incorporated Documents"). Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Notwithstanding the foregoing, unless specifically stated to the contrary, none of the information disclosed by the Registrant under Items 2.02 or 7.01 of any Current Report on Form 8-K, including the related exhibits under Item 9.01, that the Registrant may from time to time furnish to the Commission will be incorporated by reference into, or otherwise included in, this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not Applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not Applicable.

     

    Item 6: Indemnification of Officers and Directors.

     

    Indemnification

     

    In accordance with Section 145 of the Delaware General Corporation Law (the “DGCL”), Article VII of the Certificate of Incorporation grants the Company’s directors and officers a right to indemnification for all expenses, liabilities and losses relating to civil, criminal, administrative or investigative actions, suits or proceedings to which they are a party, threatened to be made a party to, or is otherwise involved in by reason of the fact that such person is or was a director or officer of the Company, or is or was a director or officer of the Company serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe their conduct was unlawful.  The Bylaws provide that the Company will indemnify the aforementioned persons, to the fullest extent permitted by the DGCL, as it presently exists or may be amended but, in the case of amendment, only to the extent that such amendment permits the Company to provide broader indemnification rights than said law permitted the Company to provide prior to such amendment. Further, Article VII of the Certificate of Incorporation provides that the Company shall indemnify directors and officers and other employees and individuals against expenses, including attorneys’ fees, judgments, fines, and amounts paid in settlement, in connection with any threatened, pending or completed action or suit by or in the right of the Company to procure a judgment in its favor, if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe their conduct was unlawful.

     

    Expenses incurred by any officer or director in defending any such action, suit or proceeding in advance of its final disposition shall be paid by us upon delivery of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified by the Company.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, Upexi has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

     

    Limitation on Liability of Directors

     

    Article VI of the Certificate of Incorporation eliminates the personal liability of directors to the Company or the Company’s stockholders for monetary damages for breach of fiduciary duty, except for: (i) any breach of loyalty to the Company or shareholders; (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of the law; (iii) for unlawful payment of dividend or unlawful stock purchase or redemptions as such is imposed under Section 174 of the DGCL; or (iv) for any transaction from which the director derived an improper personal benefit.  In addition, if the DGCL is amended to permit further elimination or limitation of the personal liability of directors, then the liability of a director of the Company shall be eliminated or limited to the fullest extent permitted by the DGCL as so amended. 

     

    Item 7. Exemption from Registration Claimed.

     

    Not Applicable. 

     

     
    3

     

     

    Item 8. Exhibits.

     

    The following exhibits are filed as part of this Registration Statement.

     

     Exhibit Number

     

    Description of Exhibit. 

     

     

     

    3.1+

     

    Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Registration Statement on Form S-1/A (333-288822), filed on August 8, 2025.

    3.2+

     

    Bylaws (incorporated by reference to Exhibit 3.2 of the Registrant’s Registration Statement on Form S-1/A (333-288822), filed on August 8, 2025.

    4.1+

     

    Description of Securities (incorporated by reference to Exhibit 4.2 of the Registrant’s Form 10-K, on September 24, 2025)

    10.1+

     

    Grove Inc. 2019 Incentive Stock Plan (incorporated by reference to Exhibit 10.1 of the Registrant’s Registration Statement on Form S-1 (file no. 333-255266), filed on April 15, 2021).

    10.2+

     

    Grove Inc. 2019 Amended and Restated Stock Incentive Plan, effective May 24, 2022 (incorporated by reference to Exhibit 4.7 of the Registrant’s Registration Statement on Form S-8 filed with the Commission on August 9, 2023).

    10.3*

     

    Upexi Inc. 2019 Amended and Restated Stock Incentive Plan, effective June 16, 2025.

    10.4*

     

    Upexi Inc. 2019 Amended and Restated Stock Incentive Plan, effective August 19, 2025.

    5.1*

     

    Opinion of Dickinson Wright PLLC re legality.

    23.1*

     

    Consent of Independent Registered Public Accounting Firm.

    23.2*

     

    Consent of Counsel (included in Exhibit 5.1 to this Registration Statement).

    24*

     

    Powers of Attorney (included on signature pages hereto).

    107*

     

    Calculation of Filing Fee Table.

     

    * Filed herewith.

    + Incorporated by reference.

     

     
    4

     

     

    Signatures

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Clearwater, Florida on September 24, 2025.

     

     

    UPEXI, INC.

     

     

     

     

    By:

    /s/ Allan Marshall

     

    Name:

    Allan Marshall

     

     

    Title:

    Chief Executive Officer

     

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints each of Allan Marshall and Andrew Norstrud as his or her true and lawful agent, proxy and attorney-in-fact, each acting alone with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to (i) act on, sign and file with the Securities and Exchange Commission any and all amendments and supplements (including post-effective amendments) to this Registration Statement on Form S-8 together with all schedules and exhibits thereto, (ii) act on, sign and file such certificates, instruments, agreements and other documents as may be necessary or appropriate in connection therewith, and (iii) take any and all actions which may be necessary or appropriate in connection therewith, granting unto such agents, proxies and attorneys-in-fact, and each of them, full power and authority to do and perform each and every act and thing necessary or appropriate to be done, as fully for all intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming that all such agents, proxies and attorneys-in-fact, any of them or any of his or her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    To effect the above, each of the undersigned has executed this Power of Attorney as of the date indicated beside each name.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and as of the dates indicated.

     

    Name

     

    Title

     

    Date

     

    /s/ Allan Marshall

     

    Chief Executive Officer, Chairman of the Board

    (Principal Executive Officer)

     

    September 24, 2025

    Allan Marshall

     

     

     

     

    /s/ Andrew J. Norstrud

     

    Chief Financial Officer, Director

    (Principal Financial Officer and Principal Accounting Officer)

     

    September 24, 2025

    Andrew J. Norstrud

     

     

     

     

    /s/ Gene Salkind

     

    Director

     

    September 24, 2025

    Gene Salkind

     

     

     

     

    /s/ Thomas Williams

     

    Director

     

    September 24, 2025

    Thomas Williams

     

     

     

     

    /s/ Lawrence H Dugan

     

    Director

     

    September 24, 2025

    Lawrence H. Dugan

     

     

     

     
    5

     

    Get the next $UPXI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPXI

    DatePrice TargetRatingAnalyst
    8/4/2025$15.00Buy
    Alliance Global Partners
    6/16/2025$16.00Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings

    $UPXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Upexi Reports Financial Results for Fiscal Year Ended June 30, 2025 and Provides Shareholders with Solana Treasury Update Since June 30, 2025

    TAMPA, Fla., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced its financial results for the fiscal year ended June 30, 2025. The annual report is available on either the SEC's website or on Upexi's IR website. Financial Highlights for the Fiscal Year ended June 30, 2025: Revenue totaled $15.8 million.Gross profit totaled approximately $10.7 million, representing a gross margin of 67%.Net loss totaled approximately $13.7 million.As of September 10, 2025, there are 58,893,261 shares of

    9/24/25 5:55:38 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Adjusted SOL per Share Increases 129% Since Treasury Launch

    Unrealized gain now stands at $142 million1 TAMPA, Fla., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today released its periodic update. "The last several weeks were extremely strong for Upexi, highlighted by a substantial increase in the price of SOL," stated Upexi CEO Allan Marshall. "As a result, our Solana treasury now stands at $447 million, including an unrealized gain of $142 million. Moreover, we continued to expand our visibility, welcoming Arthur Hayes to our newly-established Advisory Committee, and met with m

    9/11/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Participate in Upcoming September Conferences

    TAMPA, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced that management will participate in the following September 2025 investor conferences. Conference details, including links to webcasts, can be found below. 5th Annual Needham Virtual Crypto ConferenceDates: September 4, 2025Location: VirtualAttendees: Brian Rudick, Chief Strategy OfficerType: Investor Meetings H.C. Wainwright 27th Annual Global Investment ConferenceDates: September 8-10, 2025Location: Lotte New York Palace

    9/3/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    SEC Filings

    View All

    Upexi Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    9/26/25 5:20:36 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form S-8 filed by Upexi Inc.

    S-8 - UPEXI, INC. (0001775194) (Filer)

    9/24/25 5:18:57 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form S-1/A filed by Upexi Inc.

    S-1/A - UPEXI, INC. (0001775194) (Filer)

    9/24/25 5:10:38 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Salkind Gene bought $100,000 worth of shares (20,243 units at $4.94) and was granted 200,000 shares, increasing direct ownership by 60% to 585,370 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/30/25 4:47:19 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Dugan Lawrence bought $97,770 worth of shares (16,000 units at $6.11) and was granted 100,000 shares, increasing direct ownership by 29,820% to 116,389 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:05:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan bought $799,998 worth of shares (161,943 units at $4.94) and was granted 1,200,000 shares, increasing direct ownership by 154% to 2,246,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:03:08 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Salkind Gene bought $100,000 worth of shares (20,243 units at $4.94) and was granted 200,000 shares, increasing direct ownership by 60% to 585,370 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/30/25 4:47:19 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    CSO Rudick Brian Benjamin was granted 400,000 shares, increasing direct ownership by 91% to 838,597 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:09:34 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Dugan Lawrence bought $97,770 worth of shares (16,000 units at $6.11) and was granted 100,000 shares, increasing direct ownership by 29,820% to 116,389 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:05:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Upexi, Inc. with a new price target

    Alliance Global Partners initiated coverage of Upexi, Inc. with a rating of Buy and set a new price target of $15.00

    8/4/25 8:09:26 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi, Inc. upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Upexi, Inc. from Neutral to Overweight and set a new price target of $16.00

    6/16/25 7:42:40 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Leadership Updates

    Live Leadership Updates

    View All

    Upexi Establishes Advisory Committee and Welcomes Arthur Hayes as First Member

    Additional members to join the Advisory Committee in the coming weeks to optimize performance, increase visibility and unlock capital raising opportunities Arthur brings deep expertise, exposure and connectivity to both digital assets and traditional finance TAMPA, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the establishment of the Upexi Advisory Committee, composed of highly prominent individuals from the digital assets and traditional finance industries. Upexi will seek t

    8/12/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Financials

    Live finance-specific insights

    View All

    Upexi Reports Financial Results for Fiscal Year Ended June 30, 2025 and Provides Shareholders with Solana Treasury Update Since June 30, 2025

    TAMPA, Fla., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced its financial results for the fiscal year ended June 30, 2025. The annual report is available on either the SEC's website or on Upexi's IR website. Financial Highlights for the Fiscal Year ended June 30, 2025: Revenue totaled $15.8 million.Gross profit totaled approximately $10.7 million, representing a gross margin of 67%.Net loss totaled approximately $13.7 million.As of September 10, 2025, there are 58,893,261 shares of

    9/24/25 5:55:38 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Purchases 83,000 SOL, Grows Treasury to 1.9 Million SOL Worth $381 Million

    TAMPA, Fla., July 23, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the acquisition of 83,000 SOL for $16.7 million, or $201.34 per SOL. The purchase brings the Company's holdings to 1.9 million SOL worth over $381 million using the $200.60 spot price of Solana as of 5:00 pm ET yesterday. Allan Marshall, Chief Executive Officer of Upexi, remarked, "The U.S. continues to make progress around digital asset legislation, which has the potential to usher in mass adoption of blockchain technology.

    7/23/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Grows Treasury to 1.819 Million SOL Worth $331 Million with a $58 Million Unrealized Gain in Under Three Months

    Upexi purchased an additional 100,000 SOL, and anticipates it may generate up to approximately $26 million in annual staking revenue based on current SOL holdingsCompany releases adjusted metrics for enhanced transparency and analysis TAMPA, Fla., July 21, 2025 (GLOBE NEWSWIRE) --  Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the acquisition of 100,000 SOL, bringing its treasury holdings to 1,818,809 SOL worth $331 million. The recent purchase follows the successful closing of a roughly $200 million equity and c

    7/21/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    5/31/23 7:05:10 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:37:37 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

    SC 13G/A - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:36:56 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care